Shuiniujiao Dihuang Decoction With Variation for the Treatment of Psoriasis
ConditionPsoriasis Vulgaris
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorChinese University of Hong Kong
About this trial
Psoriasis is an inflammatory skin disease with huge negative impact on the quality of life of the patients, and has an overall prevalence of 2% to 3% in the general population. Plaques psoriasis is the most common type of the disease and presents red, well demarcated, and silvery plaques mainly localized in the umbilical and lumbosacral area as well as in the elbows, knees, and scalp.
Currently, pharmacological treatments such as retinoids, corticosteroids, vitamin D analogs and biologics remain the main options for most psoriasis patients. However, side effect and high cost barred many ordinary psoriasis patients from benefiting from the treatments.
A Chinese medicine formula "Shuiniujiao Dihuang Decoction with Variation (SDD)" was prescribed by Prof. Lin for many years and observed to be effective in relieving psoriasis patients' clinical manifestations.
In this study, subjects with psoriasis will be randomized into treatment group of "SDD" or placebo group for 12 weeks.
Eligibility criteria
Qualifiers
Mild to moderate chronic plaque psoriasis (PASI score 3 to 12).
Willingness to give informed consent.
Disqualifiers
Pustular or generalized erythrodermic psoriasis.
Psoriatic arthritis with syndrome of spleen-kidney yang deficiency according to Chinese medicine theory.
Systemic therapy for psoriasis 6 months prior to baseline.
Use topical medications for psoriasis 14 days prior to baseline such as retinoids, corticosteroids, vitamin D analogues, tazarotene and tacrolimus.
Trial design
Treatments tested in this trial
- SDD formula
- Placebo
Treatment groups
58 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov